Related Experiment Video
Updated: May 6, 2026

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
Published on: August 24, 2017
Liquid clues: tracking early-stage breast cancer with ctDNA - a mini review
Saumya Easaw1, Johann Hsu1, Nury Steuerwald2
1Department of Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Atrium Health, Charlotte, NC, United States.
Abstract:
Circulating tumor DNA (ctDNA) is a testing modality that has several potential applications in the management of non-metastatic breast cancer. In this mini review, we discuss its role in early detection, treatment response assessment, and surveillance for minimal residual disease (MRD). We also review technological advances that may increase assay sensitivity. Finally, we highlight key prospective therapeutic intervention trials that evaluate the incorporation of ctDNA into clinical management of early breast cancer.

